Calliditas Therapeutics to apply for delisting of common shares, ADSs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 03 2024
0mins
Should l Buy ?
Asahi Kasei's Acquisition of Calliditas: Asahi Kasei Corporation has acquired over 90% of Calliditas Therapeutics' shares and plans to initiate compulsory redemption of the remaining shares, leading to corporate actions by Calliditas' Board of Directors.
Delisting and Corporate Changes: Calliditas will apply for delisting from Nasdaq Stockholm and the Nasdaq Global Select Market, with the last trading day to be announced, and an Extraordinary General Meeting is scheduled for September 30, 2024, to elect a new Board of Directors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
